Fulgent Corp - רווח נקי למניה בארבעת הרבעונים האחרונים FLGT

Fulgent Genetics, Inc. (FLGT) management is pivoting its strategy from pandemic testing toward oncogenetics, a shift reflected in the securities' price action. The current annual EPS TTM growth value demonstrates a struggle among traders within a sideways trend, where the status is -120.40. Contracts with insurance networks provide stable revenue, while the technological superiority of US laboratories is maintained through the implementation of new diagnostic methods.
FLGT (Fulgent Genetics, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This metric measures the annual growth rate of net income per share, utilizing a 12-month rolling window to neutralize quarterly volatility. By analyzing the EPS YoY growth rate (trailing 12 months), an investor can discern the actual impact of declining diagnostic margins and insurance limit pressures on the bottom-line profitability of Fulgent Genetics, Inc. (FLGT), enabling an assessment of the business's post-pandemic resilience.